154 related articles for article (PubMed ID: 25015657)
21. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice.
Li Q; Peng X; Yang H; Wang H; Shu Y
Mol Pharm; 2011 Dec; 8(6):2476-83. PubMed ID: 21991918
[TBL] [Abstract][Full Text] [Related]
22. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.
Uhr M; Holsboer F; Müller MB
J Neuroendocrinol; 2002 Sep; 14(9):753-9. PubMed ID: 12213137
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-148b regulates megalin expression and is associated with receptor downregulation in mice with unilateral ureteral obstruction.
Wen L; Andersen PK; Husum DMU; Nørregaard R; Zhao Z; Liu Z; Birn H
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F210-F217. PubMed ID: 28331063
[TBL] [Abstract][Full Text] [Related]
24. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
25. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.
Kok T; Bloks VW; Wolters H; Havinga R; Jansen PL; Staels B; Kuipers F
Biochem J; 2003 Feb; 369(Pt 3):539-47. PubMed ID: 12381268
[TBL] [Abstract][Full Text] [Related]
27. Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.
Gu L; Chen J; Synold TW; Forman BM; Kane SE
J Pharmacol Exp Ther; 2013 Jun; 345(3):438-45. PubMed ID: 23532932
[TBL] [Abstract][Full Text] [Related]
28. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
29. Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference.
Matsui Y; Kobayashi N; Nishikawa M; Takakura Y
Pharm Res; 2005 Dec; 22(12):2091-8. PubMed ID: 16184445
[TBL] [Abstract][Full Text] [Related]
30. Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3.
Ernest S; Bello-Reuss E
Am J Physiol; 1996 Mar; 270(3 Pt 1):C910-9. PubMed ID: 8638674
[TBL] [Abstract][Full Text] [Related]
31. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.
Smith AJ; Mayer U; Schinkel AH; Borst P
J Natl Cancer Inst; 1998 Aug; 90(15):1161-6. PubMed ID: 9701366
[TBL] [Abstract][Full Text] [Related]
32. Rat Kidney Slices for Evaluation of Apical Membrane Transporters in Proximal Tubular Cells.
Arakawa H; Kubo H; Washio I; Staub AY; Nedachi S; Ishiguro N; Nakanishi T; Tamai I
J Pharm Sci; 2019 Aug; 108(8):2798-2804. PubMed ID: 30959054
[TBL] [Abstract][Full Text] [Related]
33. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
Tagen M; Zhuang Y; Zhang F; Harstead KE; Shen J; Schaiquevich P; Fraga CH; Panetta JC; Waters CM; Stewart CF
Drug Metab Lett; 2010 Dec; 4(4):195-201. PubMed ID: 20583968
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
36. The changes of calretinin immunoreactivity in paraquat-induced nephrotoxic rats.
Chang IY; Yoon SP
Acta Histochem; 2012 Dec; 114(8):836-41. PubMed ID: 22464403
[TBL] [Abstract][Full Text] [Related]
37. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines.
Dalzell AM; Mistry P; Wright J; Williams FM; Brown CD
Toxicol Lett; 2015 Jun; 235(3):189-98. PubMed ID: 25865432
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
39. Kidney-specific deletion of multidrug resistance-related protein 2 does not aggravate acute cyclosporine A nephrotoxicity in rats.
Mähler N; Freyer M; Kauschke R; Schlüter T; Steinbach AC; Oswald S; Miehe B; Krebs A; Rettig R; Grisk O
Pharmacogenet Genomics; 2012 Jun; 22(6):408-20. PubMed ID: 21869731
[TBL] [Abstract][Full Text] [Related]
40. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein.
Bao JJ; Lee BP; Stephens LC; Sahin AA; Van NT; Johnston DA; Ou CN; Kuo MT
Mol Carcinog; 2000 Oct; 29(2):103-11. PubMed ID: 11074607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
